P. jirovecii Fungi Evolved Resistance to Transplant Drugs
Study reveals that common immunosuppressive therapy may drive mutations in the fungi causing pneumonia.
Updated on Sept. 19, 2026 in Life Sciences
Live Poll
Should medical treatments be scrutinized for their potential to unintentionally strengthen dangerous pathogens?
Researchers identified mutations in the fungus P. jirovecii that grant resistance to the immunosuppressive drug mycophenolic acid. The study found these mutations were significantly more prevalent in samples from solid-organ transplant recipients compared to control groups.
Why it matters
The findings suggest that medical therapies targeting human proteins can inadvertently select for resistant fungal pathogens. This observation highlights a potential evolutionary feedback loop where standard transplant care may be driving the emergence of drug-resistant infections.
Researchers identified six common mutations in the IMPDH enzyme gene across 11 different fungal strains. Laboratory testing demonstrated that these mutated versions required higher concentrations of mycophenolic acid to achieve inhibition compared to normal enzyme versions.
The players
Science Translational Medicine
A weekly peer-reviewed medical journal that publishes research on the conversion of laboratory findings into clinical applications.
The details
The fungus P. jirovecii relies on the IMPDH enzyme—a protein that regulates cell metabolism—which shares similarities with the human enzyme targeted by mycophenolic acid. When transplant patients take the drug to suppress their immune systems, the treatment exerts selective pressure on the fungus, favoring variants that can maintain IMPDH function despite the drug's presence. Researchers verified this mechanism by producing normal and mutated versions of the enzyme in a lab to quantify the resulting shift in inhibitor sensitivity.
Timeline
2005-2019: Pneumocystis pneumonia outbreaks occurred in transplant recipient cohorts.
September 19, 2026: Study findings were published in Science Translational Medicine.
The Tech Race
This work aligns with broader efforts to map the unintended evolutionary consequences of medical treatments on the human microbiome. By linking drug exposure to specific fungal gene mutations, it provides a new benchmark for monitoring how long-term medication use alters the landscape of opportunistic pathogens.
These findings are relevant for clinicians managing solid-organ transplant patients who may face higher risks of treatment-resistant pneumonia. The study indicates that the standard use of mycophenolic acid could necessitate closer monitoring for the emergence of resistant fungal strains in this population.
The takeaway
This study demonstrates that clinical drugs can fundamentally reshape the evolution of fungi inside the human body. Future research should track whether these mutations correlate with increased rates of treatment failure in patients receiving immunosuppressive care.
Further reading
For more research on how clinical treatments influence pathogen evolution, explore the Life Sciences archives.
Source note: This article includes information reported by The Hindu.
Live Poll
Should medical treatments be scrutinized for their potential to unintentionally strengthen dangerous pathogens?
